Federico Davini
Investment Board @ A11 Venture
Lucca, Italy
Federico Davini is a seed investor at A11 Venture in Lucca focused on Health Care and Biotechnology. Federico Davini - Investment Board @ A11 Venture
- Total investments:
- 3
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Federico Davini invests in
Stages Federico Davini invests in
Countries Federico Davini invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 1 (33%)
- Biotechnology 1 (33%)
- Medical Device 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Neuron Guard, recognized as the best European startup in HEALTH category (Startup Europe Awards - SEUA 2017), is developing a life-saving medical device that aims to become the standard of care for Targeted Temperature Management (TTM) therapy. Every 7 seconds around the world a person suffers of Acute Brain Damage because of CardiovascularDiseases (CVD) and Traumatic Brain Injury (TBI). They are the most costly and prevalent killers in the last 15 years (15 million deaths by CVD in 2015), and the leading cause of disability (the global incidence rate of TBI is 200 per 100k people per year). WHO estimated a global expenditure of $ 330 billion in 2015, but it is going to increase sharply: $ 4 trillion in 2025 - including premature death, disability, and health care costs - just for CVD in LMICs. Temperature is a vital body parameter. It regulates all cellular functions so its management is essential for the good outcome of patients in several medical conditions such as cardiac arrest, stroke, traumatic brain injury, neuro and cardiac surgery, epilepsy, migraine and oncology. Regulating body temperature at a desired level makes all other treatments more effective. The most modern medical approach is the target temperature management, where physicians try to maintain the most favourable temperature for the patient for up to 24-36 hours, preventing excessive warming (fever) or cooling.Our device is a targeted temperature management system composed by a THERAPEUTIC COLLAR POWERED BY A SMART CONTROL UNIT (the size of a small briefcase). The collar transforms the neck into a natural heat exchanger exploiting several physiological and anatomical characteristics of the human body. It is quicker to act on brain tissue but can also function as total body temperature adjusting device if required. A disposable protective shield makes cleaning the collar after each use simple while featuring an optimal safety profile both in term of pathogens and allergens. The control unit collects all the data of the treatment and transmits them to the Emergency Response System. Our mission is to improve the safety of patients on the roadside, at home or in the workplace, and to reduce the costs of chronic care. In fact, Neuron Guard aims to be the only device that can be used in every circumstance, inside and outside the hospital, and allow the user to fully manage the temperature of the patient warming and cooling as necessary. Our vision is to have a Neuron Guard kit in every public place just like the Automatic External Defibrillator (AED) to empower bystanders to immediately react in case of emergency. Under this perspective our device becomes a connected-intelligent platform that takes care of the patient, connects the scene with the Emergency Response System transmitting vital data to improve the readiness and effectiveness of professional intervention.The device is patented in Italy, USA and China. We have made several prototypes in collaboration with Italian and English companies, such as Tecno Elettra Impianti and TWI, tested it in laboratory and published the experimental results on the NeuroCritical Care Journal. We have also conducted a GAP Analysis with another English consulting firm (CDP) and we are testing the human prototype internally. We are seeking to raise 2.5M€ to complete the pre-industrialization, with design and construction of the human device for the pilot trial, finalized the regulatory clearance and launch it into the market in 2019. | $635.3K / Seed / Nov 05, 2021 | ||
| Soluzioni innovative per la stampa 3D, manifattura additiva, prototipazione rapida e trattamenti superficiali dei materiali plastici | $278.1K / Seed / Jun 01, 2020 | ||
| Neuron Guard, recognized as the best European startup in HEALTH category (Startup Europe Awards - SEUA 2017), is developing a life-saving medical device that aims to become the standard of care for Targeted Temperature Management (TTM) therapy. Every 7 seconds around the world a person suffers of Acute Brain Damage because of CardiovascularDiseases (CVD) and Traumatic Brain Injury (TBI). They are the most costly and prevalent killers in the last 15 years (15 million deaths by CVD in 2015), and the leading cause of disability (the global incidence rate of TBI is 200 per 100k people per year). WHO estimated a global expenditure of $ 330 billion in 2015, but it is going to increase sharply: $ 4 trillion in 2025 - including premature death, disability, and health care costs - just for CVD in LMICs. Temperature is a vital body parameter. It regulates all cellular functions so its management is essential for the good outcome of patients in several medical conditions such as cardiac arrest, stroke, traumatic brain injury, neuro and cardiac surgery, epilepsy, migraine and oncology. Regulating body temperature at a desired level makes all other treatments more effective. The most modern medical approach is the target temperature management, where physicians try to maintain the most favourable temperature for the patient for up to 24-36 hours, preventing excessive warming (fever) or cooling.Our device is a targeted temperature management system composed by a THERAPEUTIC COLLAR POWERED BY A SMART CONTROL UNIT (the size of a small briefcase). The collar transforms the neck into a natural heat exchanger exploiting several physiological and anatomical characteristics of the human body. It is quicker to act on brain tissue but can also function as total body temperature adjusting device if required. A disposable protective shield makes cleaning the collar after each use simple while featuring an optimal safety profile both in term of pathogens and allergens. The control unit collects all the data of the treatment and transmits them to the Emergency Response System. Our mission is to improve the safety of patients on the roadside, at home or in the workplace, and to reduce the costs of chronic care. In fact, Neuron Guard aims to be the only device that can be used in every circumstance, inside and outside the hospital, and allow the user to fully manage the temperature of the patient warming and cooling as necessary. Our vision is to have a Neuron Guard kit in every public place just like the Automatic External Defibrillator (AED) to empower bystanders to immediately react in case of emergency. Under this perspective our device becomes a connected-intelligent platform that takes care of the patient, connects the scene with the Emergency Response System transmitting vital data to improve the readiness and effectiveness of professional intervention.The device is patented in Italy, USA and China. We have made several prototypes in collaboration with Italian and English companies, such as Tecno Elettra Impianti and TWI, tested it in laboratory and published the experimental results on the NeuroCritical Care Journal. We have also conducted a GAP Analysis with another English consulting firm (CDP) and we are testing the human prototype internally. We are seeking to raise 2.5M€ to complete the pre-industrialization, with design and construction of the human device for the pilot trial, finalized the regulatory clearance and launch it into the market in 2019. | $715.6K / Seed / Dec 23, 2015 |
Co-Investors
About A11 Venture
A11-Venture investe nel capitale di startup innovative nei settori della robotica, automazione, meccatronica, cleantech, web e IT. Facilita la nascita e lo sviluppo di business innovativi globali per il futuro dell'economia locale. Contribuisce a costruire aziende, lavoro qualificato, brevetti, innovazione capaci di rilanciare e riportareinvestimenti e risorse sul territorio. I soci di A11 Venture credono fermamente nell’innovazione grazie a ciò è possibile crescere per linee esterne diversificando i propri investimenti, grazie ad un portafoglio di imprese, con una forte risk mitigation derivante dalla gestione professionale di tutti processi: scouting, team building, investimenti, management degli investimenti, accelerazione e disinvestimento.
A11 Venture Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Giovanni Polidori
Founder & Investment Board
|
|||
Liban Ahmed M Varetti
Founder & Member of the Board of Investment
|
|||
|
Federico Davini
Investment Board
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Federico Davini invest in?
Federico Davini invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Seed stage. Most of the 3 investments tracked by Shizune back companies in Italy. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Federico Davini?
Public channels for Federico Davini include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Federico Davini last invest?
The most recent investment recorded for Federico Davini closed in Nov 2021. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
